-
Product Insights
NewTransitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2024
Empower your strategies with our Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2024 report and make more profitable business decisions. Transitional cell carcinoma (TCC), also known asurothelial cell carcinoma, is a type of cancer that primarily affects the transitional epithelial cells lining the urinary tract, including the bladder, ureters, and renal pelvis. It is the most common form of bladder cancer. TCC arises when these cells undergo malignant changes, often due to exposure to carcinogens like tobacco or...
-
Product Insights
NewNeuroblastoma – Drugs In Development, 2024
Empower your strategies with our Neuroblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest, or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands before spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include a lump in the abdomen or chest, weakness, bone pain, breathing problems, dark...
-
Product Insights
NewGastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024
Empower your strategies with our Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024 report and make more profitable business decisions. Gastroesophageal (GE) junction carcinomas are malignancies occurring at the point where the esophagus meets the stomach. Typically classified as adenocarcinomas or squamous cell carcinomas, adenocarcinomas are more prevalent. Risk factors include chronic gastroesophageal reflux disease (GERD), obesity, and smoking. Symptoms often manifest in advanced stages, including difficulty swallowing, weight loss, and abdominal pain. Diagnosis involves endoscopic procedures and imaging studies....
-
Product Insights
NewLiposarcoma – Drugs In Development, 2024
Empower your strategies with our Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Liposarcoma is a rare tumor derived from fat tissue that occurs in the “soft tissues” of the body (soft tissue sarcoma). It is classified as a cancer (malignant) because of its potential to recur locally and spread to other areas of the body. The severity of disease depends on the subtype of the liposarcoma and the presenting stage of the primary tumor....
-
Product Insights
NewNon-Small Cell Lung Carcinoma – Drugs In Development, 2024
Empower your strategies with our Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. “Non-small cell” refers to the way cancer cells look under a microscope. If the cells look small, the cancer is referred to as small cell lung cancer (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADPA-2M4CD8 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADPA-2M4CD8 in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADPA-2M4CD8 in Fallopian Tube Cancer Drug Details: ADP-A2M4CD8 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-0742 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KB-0742 in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KB-0742 in Small-Cell Lung Cancer Drug Details: KB-0742 is under...
-
Company Profile
Adaptimmune Ltd – Company Profile
Adaptimmune Ltd (Adaptimmune), a subsidiary of Adaptimmune Therapeutics plc is a biopharmaceutical company. It includes developing T-cell receptors for T-cell therapy and SPEAR TCR therapies to utilize the body’s immune system. Adaptimmune’s product pipeline includes ADP-A2M10 (MAGE-A10) for melanoma, urothelial cancer, ADP-A2M4 (MAGE-A4) for synovial sarcoma, myxoid cell liposarcoma, ovarian cancer, ADP-A2AFP (AFP) for liver cancer. Its clinical trials include multiple myeloma trial, synovial sarcoma trial, ovarian cancer trial, non-small cell lung cancer (NSCLC). The company also provides pre-clinical testing...
Add to Basket